Helena Jernström

författare

• 2013
  • Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status.
  • Given breast cancer, is fat better than thin? Impact of the estrogen receptor beta gene polymorphisms.
• 2012
  • Breast cancer and spider telangiectasias at diagnosis and its relation to histopathology and prognosis: a population-based study.
  • Clinical Profiles Predict Early Nonadherence to Adjuvant Endocrine Treatment in a Prospective Breast Cancer Cohort
  • Clinical profiles predict early non-adherence to adjuvant endocrine treatment in a prospective breast cancer cohort.
  • Given breast cancer, does breast size matter? Data from a prospective breast cancer cohort.
  • Increased incidence of childhood, prostate and breast cancers in relatives of childhood cancer patients.
• 2011
  • Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients.
  • Androgen receptor htSNPs in relation to androgen levels and OC use in young women from high-risk breast cancer families.
  • Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers
  • Development of a scoring rubric for A to F grading and assessment of Master’s Theses that are using quantitative methodology
  • Emergency cesarean sections can be predicted by markers for stress, worry and sleep disturbances in first-time mothers.
  • Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
  • IGF1 htSNPs in relation to IGF-1 levels in young women from high-risk breast cancer families: implications for early-onset breast cancer
  • IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families.
  • Natural remedy use in a prospective cohort of breast cancer patients in southern Sweden.
• 2010
  • Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction
  • Interactions between oral contraceptive status and GSTM1 and GSTT1 deletions on insulin-like growth factor-1 (IGF-1) plasma levels in young healthy women.
• 2009
  • CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients.
  • Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
  • IGF1 and IGFBP3 Polymorphisms and Plasma Levels in Women
• 2008
  • Coffee Consumption and CYP1A2*1F Genotype Modify Age at Breast Cancer Diagnosis and Estrogen Receptor Status.
  • Coffee intake and CYP1A2*1F genotype predict breast volume in young women: implications for breast cancer.
  • Polygenes, risk prediction, and targeted prevention of breast cancer
  • Prolactin levels, breast-feeding and milk production in a cohort of young healthy women from high-risk breast cancer families: implications for breast cancer risk.
• 2007
  • Absence of the common IGF1 19 CA-repeat allele is more common among BRCA1 mutation carriers than among non-carriers from BRCA1 families.
  • Absence of the common Insulin-like growth factor-1 19-repeat allele is associated with early age at breast cancer diagnosis in multiparous women.
  • CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women
  • Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women
• 2006
  • Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16 alpha-hydroxyestrogen metabolites
  • Differences in IGFBP-3 regulation between young healthy women from BRCAX families and those belonging to BRCA1/2 families.
  • Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
  • Moderate coffee and alcohol consumption improves the estrogen metabolite profile in adjuvant treated breast cancer patients: A pilot study comparing pre- and post-operative levels
  • Of cup and bra size: Reply to a prospective study of breast size and premenopausal breast cancer incidence.
• 2005
  • High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: Implications for breast and ovarian cancer risk.
  • Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing
  • Insulin-like growth factor-1 (IGF1) genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating IGF-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families.
  • Naturläkemedel och hormonpreparat ­ potentiell risk för bröstcancerpatienter. Studie kartlägger bruk av medel som kanske motverkar behandlingen
  • Prevalence of urinary incontinence in relation to self-reported depression, intake of serotonergic antidepressants, and hormone therapy in middle-aged women: a report from the Women's Health in the Lund Area study.
• 2004
  • Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
• 2003
  • A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden)
  • Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value
  • Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups.
• 2002
  • Familial and hormonal risk factors for papillary serous uterine cancer
  • Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
• 2001
  • CYP gene polymorphisms and early menarche
  • Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women
  • Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk
  • Re: CYP17 promoter polymorphism and breast cancer in Australian women under age forty years
• 1999
  • Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients
  • Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study
  • Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2
  • Reproductive factors in hereditary breast cancer
• 1998
  • BRCA1-positive patients are small for gestational age compared with their unaffected relatives
  • Do BRCA1 mutations affect the ability to breast feed? Significantly shorter length of breast feeding among BRCA1 mutation carriers compared with their unaffected relatives.
  • Insulin-like growth factor-1 in relation to adult weight and birth weight in healthy nulliparous women
• 1997
  • Breast size in relation to endogenous hormone levels, body constitution, and oral contraceptive use in healthy nulligravid women aged 19-25 years
  • Reduced testosterone, 17 beta-oestradiol and sexual hormone binding globulin, and increased insulin-like growth factor-1 concentrations, in healthy nulligravid women aged 19-25 years who were first and/or second degree relatives to breast cancer patients
• 1996
  • Effects of Oral Contraceptives on Endogenous Hormones, Body Constitution, and Breast Epithelium in Healthy, Young Women
  • Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors
• 1995
  • Temporary increase of FSH levels in healthy, nulliparous, young women after cessation of low-dose oral contraceptive use
• 1994
  • Suppression of plasma insulin-like growth factor-1 levels in healthy, nulliparous, young women using low dose oral contraceptives
• 1992
  • Plasma prolactin in relation to menstrual cycle phase, oral contraceptive use, arousal time and smoking habits